|
|
|
|
|
|
|
|
|
|
|
22.10.25 - 14:06
|
Evolus to Report Third Quarter Financial Results on November 5, 2025 (Business Wire)
|
|
|
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its third quarter 2025 financial results on Wednesday, November 5, 2025, after the U.S. financial markets close.
Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's remarks.
To participate in the conference call, dial (877) 407-6184 (U.S.) or (201) 389-0877 (international) or connect live via webcast on the Investor Relations page of the Evolus website here.
Following the completion of the call, a telephonic replay can be accessed by dialing (877) 660-6853 (U.S.) or (201) 612-7415 (international) and using conference number 13756397. An archived webcast can also be accessed on the Investor Relations page of the Evolus website at www.evolus.com.
About Evolus, Inc.
Evolus (NASDAQ: EOLS) i...
|
|
|
10.10.25 - 22:06
|
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
|
|
|
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in October of non-qualified stock options to purchase an aggregate of 24,931 shares of Evolus and an aggregate of 31,116 restricted stock units (RSUs) of the company's common stock to 9 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company's board of directors under the Evolus 2023 Inducement Incentive Plan, with a grant and vesting commencement date of October 7, 2025, as an inducement material to the new employees entering into employment with Evolus in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of $6.26 per share, the closing price of the company's common stock on October 7, 2025. The stock options have a 10-year term and vest over 4 years, with 25% of the number of shares subject to the option vesti...
|
|
|
|
|
12.09.25 - 23:36
|
Evolus Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
|
|
|
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 8,744 shares of Evolus common stock and an aggregate of 15,000 restricted stock units (RSUs) of the company's common stock to 6 newly hired non-executive employees of the company, and 143,403 shares of Evolus common stock and 104,603 RSUs of the company's common stock to Tatjana Mitchell, the company's new Chief Financial Officer. The awards were approved by the compensation committee of the company's board of directors under the Evolus 2023 Inducement Incentive Plan as an inducement material to the new employees entering into employment with Evolus in accordance with Nasdaq Listing Rule 5635(c)(4), with the non-executive employee awards and Ms. Mitchell's awards having a grant date and vesting commencement date of September 7, 2025 and September 8, 2025,...
|
|
|
|
|
|
|
|
|
08.08.25 - 22:06
|
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
|
|
|
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in August of an aggregate of 12,731 restricted stock units (RSUs) of the company's common stock to 5 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company's board of directors under the Evolus' 2023 Inducement Incentive Plan, with a grant date of August 7, 2025 and a vesting commencement date of the 7th day of the month following each employee's employment start date, as an inducement material to the new employees entering into employment with Evolus in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs vest 25% on each annual anniversary of the vesting commencement date. The awards are subject to the terms and conditions of the 2023 Inducement Incentive Plan and the terms and conditions of the stock option agreement or RSU agreement, as app...
|
|
|
|
|
|
|
|
|
|
|
05.08.25 - 22:09
|
Evolus Reports Second Quarter 2025 Financial Results and Provides Business Updates (Business Wire)
|
|
|
Global Net Revenue of $69.4 Million for Q2 2025, Up 4% from Q2 2024 in a Market Where Overall U.S. Aesthetic Procedures Decreased; Growth Driven by the Successful Launch of Evolysse™ and Continued Strength in International Markets
Evolysse™ Delivered $9.7 Million in Revenue for Q2 2025, Marking the Strongest Filler Launch Quarter in Over a Decade and Providing a Solid Foundation for Second Half Growth
Expects to Achieve Meaningful Profitability1 in Q4 2025 and Annual Profitability1 Beginning in 2026; Strategic Cost Structure Optimization Expected to Yield At Least $25 Million in Non-GAAP Operating Expense Savings for 2025
Resets 2025 Net Revenue Guidance to $295 Million to $305 Million; Rebases 2025 Non-GAAP Operating Expenses to $208 Million to $213 Million; Maintains Projected Total Net Revenue Goal of $700 Million and Non-GAAP Operating Income Margin of 20% by 2028
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic...
|
|
|
22.07.25 - 14:12
|
Evolus to Report Second Quarter Financial Results on August 5, 2025 (Business Wire)
|
|
|
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its second quarter 2025 financial results on Tuesday, August 5, 2025, after the U.S. financial markets close.
Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's remarks.
To participate in the conference call, dial (877) 407-6184 (U.S.) or (201) 389-0877 (international) or connect live via webcast on the Investor Relations page of the Evolus website here.
Following the completion of the call, a telephonic replay can be accessed by dialing (877) 660-6853 (U.S.) or (201) 612-7415 (international) and using conference number 13754888. An archived webcast can also be accessed on the Investor Relations page of the Evolus website at www.evolus.com.
About Evolus, Inc.
Evolus (NASDAQ: EOLS) is a...
|
|
|
11.07.25 - 22:06
|
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
|
|
|
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in July of an aggregate of 12,385 restricted stock units (RSUs) of the company's common stock to 6 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company's board of directors under the Evolus' 2023 Inducement Incentive Plan, with a grant date and vesting commencement date of July 7, 2025, as an inducement material to the new employees entering into employment with Evolus in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs vest 25% on each annual anniversary of the vesting commencement date. The awards are subject to the terms and conditions of the 2023 Inducement Incentive Plan and the terms and conditions of the stock option agreement or RSU agreement, as applicable, covering the grant, including requirements to remain continuously employed...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
